{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:02:48Z","timestamp":1790874168258,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clml.2026.07.019","type":"journal-article","created":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T06:26:37Z","timestamp":1785565597000},"page":"649-660","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting the Menin\u2013KMT2A Axis in AML: Translating Molecular Insights into Therapeutic Success"],"prefix":"10.1016","volume":"26","author":[{"given":"Claudia","family":"Simio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Vatteroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clml.2026.07.019_bib0001","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/CCO.0000000000001185","article-title":"The role of menin inhibitors in acute myeloid leukemia","volume":"37","author":"Isidori","year":"2025","journal-title":"Curr Opin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.07.019_bib0002","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s40364-025-00786-y","article-title":"Insights into KMT2A rearrangements in acute myeloid leukemia: from molecular characteristics to targeted therapies","volume":"13","author":"Zehtabcheh","year":"2025","journal-title":"Biomark Res"},{"issue":"22","key":"10.1016\/j.clml.2026.07.019_bib0003","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16223743","article-title":"Targeting menin in acute myeloid leukemia: therapeutic advances and future directions","volume":"16","author":"Dhiman","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.clml.2026.07.019_bib0004","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3390\/biomedicines14010219","article-title":"Menin inhibition in acute myeloid leukemia: pathobiology, progress and promise","volume":"14","author":"Joshi","year":"2026","journal-title":"Biomedicines"},{"issue":"11","key":"10.1016\/j.clml.2026.07.019_bib0005","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.3324\/haematol.2022.282621","article-title":"Revumenib for patients with acute leukemia: a new tool for differentiation therapy","volume":"109","author":"Salman","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.07.019_bib0006","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1200\/JCO-25-01694","article-title":"Ziftomenib in relapsed or refractory NPM1-mutated AML","volume":"43","author":"Wang","year":"2025","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2026.07.019_bib0007","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/17501911.2025.2485019","article-title":"Menin: from molecular insights to clinical impact","volume":"17","author":"Brown","year":"2025","journal-title":"Epigenomics"},{"issue":"8","key":"10.1016\/j.clml.2026.07.019_bib0008","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1111\/febs.70460","article-title":"Current perspectives on KMT2A fusion proteins and menin inhibition in paediatric acute myeloid leukaemia","volume":"293","author":"Roets","year":"2026","journal-title":"FEBS J"},{"issue":"1","key":"10.1016\/j.clml.2026.07.019_bib0009","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s41698-025-01200-4","article-title":"Dysregulation of HOXA genes in acute myeloid leukemia and targeted therapy","volume":"9","author":"Huang","year":"2025","journal-title":"NPJ Precis Oncol"},{"issue":"2","key":"10.1016\/j.clml.2026.07.019_bib0010","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/ijc.35332","article-title":"Targeting the Menin-KMT2A interaction in leukemia: lessons learned and future directions","volume":"158","author":"Perner","year":"2026","journal-title":"Int J Cancer"},{"issue":"25","key":"10.1016\/j.clml.2026.07.019_bib0011","doi-asserted-by":"crossref","first-page":"7118","DOI":"10.1016\/j.cell.2025.10.010","article-title":"Disparate leukemia mutations converge on nuclear phase-separated condensates","volume":"188","author":"Datar","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.clml.2026.07.019_bib0012","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-026-02959-6","article-title":"Overcoming MEN1-mediated resistance with menin inhibitor switching in KMT2A-rearranged acute myeloid leukemia","author":"Chin","year":"2026","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.clml.2026.07.019_bib0013","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000935","article-title":"The MLL\u2013Menin interaction is a therapeutic vulnerability in NUP98-rearranged AML","volume":"7","author":"Rasouli","year":"2023","journal-title":"HemaSphere"},{"issue":"4","key":"10.1016\/j.clml.2026.07.019_bib0014","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3390\/cells15040338","article-title":"Inside the battle against Acute myeloid leukemia: biology, breakthroughs, and hope","volume":"15","author":"Bao","year":"2026","journal-title":"Cells"},{"issue":"17","key":"10.1016\/j.clml.2026.07.019_bib0015","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood.2021011917","article-title":"Menin inhibition decreases bcl-2 and synergizes with venetoclax in NPM1\/FLT3-mutated AML","volume":"138","author":"Carter","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.07.019_bib0016","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1021\/acs.chemrev.6b00801","article-title":"Inhibitors of protein methyltransferases and demethylases","volume":"118","author":"Kaniskan","year":"2018","journal-title":"Chem Rev"},{"issue":"2","key":"10.1016\/j.clml.2026.07.019_bib0017","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3390\/hematolrep16020024","article-title":"A 2024 update on menin inhibitors. A new class of target agents against KMT2A-rearranged and NPM1-mutated acute myeloid leukemia","volume":"16","author":"Candoni","year":"2024","journal-title":"Hematol Rep"},{"issue":"1","key":"10.1016\/j.clml.2026.07.019_bib0018","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin inhibition with Revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2026.07.019_bib0019","article-title":"Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial","volume":"25","author":"Wang","year":"2024","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clml.2026.07.019_bib0020","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.3324\/haematol.2024.285616","article-title":"Bleximenib, the novel menin-KMT2A inhibitor JNJ-75276617, impairs long-term proliferation and immune evasion in acute myeloid leukemia","volume":"110","author":"Hogeling","year":"2025","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2026.07.019_bib0021","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1182\/hematology.2025000755","article-title":"The promise of menin inhibitors: from approval to triplet regimens","volume":"2025","author":"Thakur","year":"2025","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.07.019_bib0022","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-173149","article-title":"Covalent menin inhibitor Bmf-219 in patients with relapsed or refractory (R\/R) acute leukemia (AL): preliminary phase 1 data from the Covalent-101 study","volume":"142","author":"Lancet","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2026.07.019_bib0023","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13045-025-01757-4","article-title":"A phase 1\/2 study of DS-1594 menin inhibitor in relapsed\/refractory acute leukemias","volume":"18","author":"Senapati","year":"2025","journal-title":"J Hematol Oncol"},{"issue":"10","key":"10.1016\/j.clml.2026.07.019_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.107777","article-title":"Drug-resistant menin variants retain high binding affinity and interactions with MLL1","volume":"300","author":"Ray","year":"2024","journal-title":"J Biol Chem"},{"issue":"19","key":"10.1016\/j.clml.2026.07.019_bib0025","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/blood.2023023644","article-title":"Epigenetic regulation of noncanonical menin targets modulates menin inhibitor response in acute myeloid leukemia","volume":"144","author":"Zhou","year":"2024","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2026.07.019_bib0026","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14071689","article-title":"Refining AML treatment: the role of genetics in response and resistance evaluation to new agents","volume":"14","author":"Halik","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"20","key":"10.1016\/j.clml.2026.07.019_bib0027","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1182\/blood.2023022832","article-title":"BRG1\/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor","volume":"143","author":"Fiskus","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2026.07.019_bib0028","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1182\/bloodadvances.2025018178","article-title":"Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure","volume":"10","author":"Chin","year":"2026","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.clml.2026.07.019_bib0029","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.5c03128","article-title":"Development of DOT1L-targeted protein degraders for treating MLL-r leukemia","volume":"69","author":"Quan","year":"2026","journal-title":"J Med Chem."},{"issue":"6","key":"10.1016\/j.clml.2026.07.019_bib0030","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1158\/2643-3230.BCD-24-0212","article-title":"Combination strategies with menin inhibitors for acute leukemia","volume":"6","author":"Issa","year":"2025","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.clml.2026.07.019_bib0031","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1200\/JCO-25-00914","article-title":"Azacitidine, venetoclax, and revumenib for newly diagnosed NPM1-mutated or KMT2A-rearranged AML","volume":"43","author":"Zeidner","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.07.019_bib0032","doi-asserted-by":"crossref","first-page":"S390","DOI":"10.1016\/j.jtct.2025.12.560","article-title":"Bleximenib in combination with intensive chemotherapy: a phase 1b study in patients with newly diagnosed acute myeloid leukemia with KMT2A or NPM1 alterations transplantation and cellular therapy","volume":"32","author":"D\u00f6hner","year":"2026","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.clml.2026.07.019_bib0033","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17132095","article-title":"NPM1-Mutated AML: deciphering the molecular and clinical puzzle in the era of novel treatment strategies","volume":"17","author":"Diamantidis","year":"2025","journal-title":"Cancers"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.07.019_bib0034","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2025-3461","article-title":"Post-transplant maintenance with revumenib in children with HOX-driven AML","volume":"146","author":"Cuglievan","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.07.019_bib0035","article-title":"Menin inhibitors in KMT2A-rearranged and NPM1-mutated acute leukemia: a scoping review of safety and efficacy","volume":"213","author":"Al Dali","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"10.1016\/j.clml.2026.07.019_bib0036","doi-asserted-by":"crossref","first-page":"4","DOI":"10.32604\/or.2025.072443","article-title":"Clinical integration of Menin inhibitors in AML: evolving data and therapeutic perspectives","volume":"34","author":"Chen","year":"2026","journal-title":"Oncol Res"},{"key":"10.1016\/j.clml.2026.07.019_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1696229","article-title":"Acute myeloid leukemia drug resistance: targetable nodes and the clinical trajectory of small-molecule inhibitors","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.clml.2026.07.019_bib0038","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12885-025-13633-y","article-title":"Identification of HOXA9 methylation as an epigenetic biomarker predicting prognosis and guiding treatment choice in acute myeloid leukemia","volume":"25","author":"Xie","year":"2025","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.clml.2026.07.019_bib0039","doi-asserted-by":"crossref","DOI":"10.3390\/diseases13070227","article-title":"Therapeutic implications of menin inhibitors in the treatment of acute leukemia: a critical review","volume":"13","author":"Canichella","year":"2025","journal-title":"Diseases"},{"issue":"2","key":"10.1016\/j.clml.2026.07.019_bib0040","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3904\/kjim.2016.244","article-title":"Targeting the CXCL12\/CXCR4 axis in acute myeloid leukemia: from bench to bedside","volume":"32","author":"Cho","year":"2017","journal-title":"Korean J Intern Med"},{"issue":"7","key":"10.1016\/j.clml.2026.07.019_bib0041","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood.2023021359","article-title":"Acute myeloid leukemias with UBTF tandem duplications are sensitive to menin inhibitors","volume":"143","author":"Barajas","year":"2024","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026002442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026002442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:17:33Z","timestamp":1790871453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026002442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2152265026002442"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.07.019","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the Menin\u2013KMT2A Axis in AML: Translating Molecular Insights into Therapeutic Success","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}